Combination therapy for visceral leishmaniasis.
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp 2000, Belgium. jvangriensven@itg.be
Johan
J
van Griensven
Marleen
M
Boelaert
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D007194:India; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D010303:Paromomycin / Q000008:administration & dosage* / Q000009:adverse effects; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016032:Randomized Controlled Trials as Topic
D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D010767:Phosphorylcholine; C039128:miltefosine; D010303:Paromomycin; D000666:Amphotericin B